by Mark L. Ratner
In June, the Stryker Biotech division of Stryker Corp. completed its US regulatory filing for OP-1, the first...
Orthobiologics are now on the horizon, driving suppliers to increase R&D spending. The goal is to develop high-margin products that will actively promote bone formation. Has the slow progress to commercialization of the first two products--bone morphogenic proteins developed by the collaborations of Stryker Corp/Creative Biomolecules and Genetics Institute/Sofamor Danek--helped prime the market to accept a new technology? Or has the perception of delay dampened enthusiasm and scared off some of the big orthopedics players?
by Mark L. Ratner
In June, the Stryker Biotech division of Stryker Corp. completed its US regulatory filing for OP-1, the first...